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OBJECTIVES: In 2003 a restrictive reimbursement scheme,
advocating increased individual reimbursement versus general
reimbursement of new important pharmaceuticals, was imple-
mented in Norway. This study was conducted 18 months after
implementation, and investigates physician self-reported atti-
tudes to and experience with the scheme from a clinical and
administrative perspective. METHODS: Practicing physicians (n
= 1399) from the NMA Research Panel were surveyed (73 ques-
tion self-administered questionnaire) by mail, December 2004.
The response rate was 71% (n = 993). Only data from respon-
dents involved with the scheme in 2004 (n = 605; 61%) were
analysed in this sub-study of 24 questions. Physicians’ attitudes
and experience were addressed through 17 claims about the
scheme and evaluated on Likert scales, in addition to questions
on resource use and number of applications, referrals and appli-
cation approvals/rejections. RESULTS: Of the 605 respondents
in this sub-study, 87% agreed that the individual reimbursement
scheme was complicated and demanding. Only 37% reported
approval of all applications. Rejected applications were appealed
by 26% of the physicians, 31% re-submitted/-referred to spe-
cialists, 22% requested written justiﬁcation, 21% recommended
patients to pay for the pharmaceutical themselves, whilst 14%
did nothing. The majority of physicians (71%) were dissatisﬁed
with the scheme and 54% were dissatisﬁed with the application-
process. In contrast, only 11% were satisﬁed with the scheme
and 14% with the application-process. Fifty-seven percent
reported that the scheme restricted physicians from prescribing
the pharmaceutical they consider clinically best for a patient and
52% of patients choose to pay for the pharmaceutical them-
selves. Self-reported use of time to administrate individual appli-
cations (n = 110,000), was estimated to 11 physician-labour
years and a cost of 42 million NOK in 2004. CONCLUSIONS:
The majority of physicians in Norway are dissatisﬁed with the
governments increased use of individual reimbursement. The
results indicate that the scheme generates high administrative
costs and may have negative consequences for patients.
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TELEMEDICINE IN THE U.S. MEDICARE PROGRAM: 2007
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OBJECTIVE: Reform legislation has expanded the U.S.
Medicare program for eligible telemedicine services and has
required establishment of a process to add or delete covered ser-
vices on an annual basis. This study explores the current reim-
bursement status of Medicare telemedicine reimbursement and
its potential implications for 2007. METHODS: The Medicare
rationale and historic progress of telemedicine coverage and
reimbursement was constructed within a worksheet format.
Major changes and additions to the program were highlighted
and examined. A timeline of legislative and regulatory decisions
was prepared. Criteria for coverage and payment were identiﬁed
and summarized. Current deﬁnitions of required equipment and
exceptions to these requirements were identiﬁed and their evo-
lution tracked. The potential for 2007 reimbursement changes
was evaluated. RESULTS: A summary of ﬁndings follows. The
Medicare telemedicine program contains four major covered
types of service that can now be performed by eight categories
of speciﬁed professionals. Two types of geographic areas are eli-
gible, although certain demonstration programs may be eligible
regardless of geographic location. Billing and payment requires
the use of stipulated codes. The process to add or delete services
annually has been implemented. Each transaction must contain
two sites; “distant” and “originating”. There are ﬁve types of
originating sites. Payment is funded differently for “distant”
versus “originating”. The required equipment is primarily rep-
resented by interactive telecommunications systems, although
asynchronous technology is allowed in restricted instances. An
upcoming Medicare report to Congress may recommend further
expansion of the telemedicine program in 2007. CONCLU-
SIONS: Medicare telemedicine coverage and payment has con-
tinued to expand but remains restricted to certain geographic
areas and to certain service provider sites. Health care decision-
makers, including managers and payers, must be made better
aware of the multiple beneﬁts and efﬁciencies that telemedicine
offers to both service providers and to patients.
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OBJECTIVES: To estimate volumes and structure of consump-
tion of the drugs received by separate categories of citizens which
have the right to free-of-charge reception under reimbesment
program (DLO) in 2005 in Tatarstan (on example Tatarstan
region). To allocate diseases having the greatest prevalence and-
or the greatest ﬁnancial loading for budget. METHODS: In 2004
there was not the federal reimbursement system. In 2005 DLO
was launched. A total of 216,722 persons have the right to
receive drugs by DLO. We received the information on each of
2,543,599 purposes of drugs. Ischemic illness of heart, hyper-
tonic illness, diabetes, cancer of a mammary gland were leaders
on volume. Expenses Ischemic illness of heart, hypertonic illness,
diabetes, cancer of a mammary gland were leaders on volume 
of expense. One thousand patients with these diagnosis were 
randomized. We compared their therapy in 2004 vs. 2005.
RESULTS: Total cost of DLO in Tatarstan in 2005 was
€26,368,244. Average cost of one recipe in 2005 in DLO was
€10.5. Average expenses for one patient in 2005 a year in DLO
was €124. The maximal expenses for one patient was €23,534.
On ischemic illness of heart 7% of charges are necessary, arter-
ial hypertension 9%, diabetes 16%, oncology 19%. CONCLU-
SION: Introduction of system of reimbesment has rendered
beneﬁcial effect on quality of treatment of patients 2005 vs. 2004
percentage of patients on a regular basis received drug therapy
in occasion of cardiovascular diseases (with the miss no more
than three months for a year) has grown from 15,8% up to
32.8%.
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GENERIC COMPETITION: EFFECT ON PRICES AND
SUBSTITUTION EFFECTS
Engstrom A, Lundin D, Jacob J
LFN Pharmaceutical Beneﬁts Board, Solna, Sweden
OBJECTIVES: To calculate a price index for pharmaceuticals in
Sweden and to examine the effects of generic competition on
patented pharmaceuticals. METHODS: Price and volume data
